Xbiotech announces first patient begins novel natrunix therapy in phase ii rheumatoid arthritis (ra) clinical trial

Austin, texas, aug. 08, 2023 (globe newswire) -- xbiotech inc. (nasdaq: xbit) today began treating the first patient in a phase ii, double-blind, placebo-controlled, randomized clinical study to evaluate natrunix as a new treatment for arthritis. natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (ra).
XBIT Ratings Summary
XBIT Quant Ranking